arrow
Ž

Žiga Rotar

department of rheumatology
H指数:26
被引数:2,277

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Progression of sacroiliac joint structural lesions in axial spondyloarthritis: a longitudinal comparative study of MRI and radiography among European patients in routine clinical care

轴性脊柱关节炎患者骶髂关节结构病变的进展:欧洲常规临床护理中患者的MRI与放射影像纵向比较研究

2026-10-130
OAAI
Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritis

定义并验证改良纽约标准放射学部分的高特异性MRI截断值在轴性脊柱关节炎患者中的应用

2026-07-170
OA
Defining Bath Ankylosing Spondylitis Disease Activity Index Cut-off Values for Disease Activity States in a Multinational European Cohort of Patients With Axial Spondyloarthritis

定义巴思强直性脊柱炎疾病活动指数(BASDAI)截断值,以评估欧洲多国轴性脊柱关节炎患者队列中的疾病活动状态。

2025-12-020
OAAI
Sacroiliac joint involvement in psoriatic arthritis – MRI, radiographic and clinical findings in 581 European routine care patients

银屑病关节炎中骶髂关节的受累情况——581例欧洲常规护理患者的MRI、放射影像学和临床发现

2025-10-030
OA
Disparities in the organisation of national healthcare systems for treatment of patients with psoriatic arthritis and axial spondyloarthritis across Europe

欧洲各国在组织治疗银屑病关节炎和轴向脊柱关节炎患者方面的国家医疗体系存在差异。

2025-06-010
OAAI
Incidence of Major Adverse Cardiovascular Events in Patients With Rheumatoid Arthritis Treated With JAK Inhibitors Compared With Biologic Disease-Modifying Antirheumatic Drugs: Data From an International Collaboration of Registries

与生物制剂改善病情的抗风湿药物相比,接受JAK抑制剂治疗的风湿性关节炎患者发生主要不良心血管事件的发生率:来自国际注册研究合作的数据

2025-05-210
OAAI
Four-year secukinumab treatment outcomes in European real-world patients with axial spondyloarthritis and psoriatic arthritis
2025-05-011
OAAI
Handling of missing component information for common composite score outcomes used in axial spondyloarthritis research when complete-case analysis is unbiased
2025-02-280
OAAI
Comparing DAPSA, DAPSA28, and DAS28-CRP in Patients With Psoriatic Arthritis Initiating a First Tumor Necrosis Factor Inhibitor Across Nine European Countries
2024-08-190
OAAI
Drug effectiveness of 2nd and 3rd TNF inhibitors in psoriatic arthritis - relationship with the reason for withdrawal from the previous treatment
2024-07-011
OAAI
THE IMPACT OF SMOKING STATUS ON ONE-YEAR SECUKINUMAB RETENTION RATE IN 1,684 PATIENTS WITH PSORIATIC ARTHRITIS: REAL-WORLD RESULTS FROM THE EUROSPA COLLABORATION

吸烟状况对1,684例银屑病关节炎患者一年SECUKINUMAB保留率的影响:EUROSPA合作的真实世界结果

2024-06-010
PRE
DIFFERENTIAL JOINT-LEVEL RESPONSES TO TNF INHIBITORS IN PSORIATIC ARTHRITIS: A COLLABORATIVE EUROPEAN OBSERVATIONAL COHORT STUDY

银屑病关节炎中肿瘤坏死因子抑制剂引起的关节水平差异反应:一项欧洲合作性观察队列研究

2024-06-010
PRE
Cut-Offs for Disease Activity States in Axial Spondyloarthritis With Ankylosing Spondylitis Disease Activity Score (ASDAS) Based on C-Reactive Protein and ASDAS Based on Erythrocyte Sedimentation Rate: Are They Interchangeable?
2024-04-151
OA
Oral glucocorticoid use in patients with rheumatoid arthritis initiating TNF-inhibitors, tocilizumab or abatacept: Results from the international TOCERRA and PANABA observational collaborative studies
2024-03-012
OAAI
Sex Differences in the Effectiveness of First-Line Tumor Necrosis Factor Inhibitors in Psoriatic Arthritis: Results From the European Spondyloarthritis Research Collaboration Network
2024-02-253
OAAI